Altered urinary sodium excretion response after central cholinergic and adrenergic stimulation of adult spontaneously hypertensive rats

Nelson A. Lutaif • Lívia M. Gontijo • José F. Figueiredo • José A. R. Gontijo

Abstract In this study, we hypothesized that blunting of the natriuresis response to intracerebroventricularly (i.c.v.) microinjected cholinergic and adrenergic agonists is involved in the development of hypertension in spontaneously hypertensive rats (SHR). We evaluated the effect of i.c.v. injection of cholinergic and noradrenergic agonists, at increasing concentrations, and of muscarinic cholinergic and \(\alpha_1\) and \(\alpha_2\)-adrenoceptor antagonists on blood pressure and urinary sodium handling in SHR, compared with age-matched Wistar Kyoto rats (WR). We confirmed that CCh and NE microinjected into the lateral ventricle (LV) of conscious rats leads to enhanced natriuresis. This response was associated with increased proximal and post-proximal sodium excretion accompanied by an unchanged rate of glomerular filtration. We showed that cholinergic-induced natriuresis in WR and SHR was attenuated by previous i.c.v. administration of atropine and was significantly lower in the hypertensive strain than in WR. In both groups the natriuretic effect of injection of noradrenaline into the LV was abolished by previous local injection of an \(\alpha_1\)-adrenoceptor antagonist (prazosin). Conversely, LV \(\alpha_2\)-adrenoceptor antagonist (yohimbine) administration potentiated the action of noradrenaline. The LV yohimbine pretreatment normalized urinary sodium excretion in SHR compared with age-matched WR. In conclusion, these are, as far as we are aware, the first results showing the importance of interaction of central cholinergic and/or noradrenergic receptors in the pathogenesis of spontaneous hypertension. These experiments also provide good evidence of the existence of a central adrenergic mechanism consisting of \(\alpha_1\) and \(\alpha_2\)-adrenoceptors which works antagonistically on regulation of renal sodium excretion.

Keywords Central nervous system • Renal function • Natriuresis • Intracerebroventricular • Cholinergic system • Adrenergic system • Hypertension • SHR

Abbreviations

0.15 M NaCl Vehicle
Atr Selective cholinergic (atropine) antagonist
AV3V Anterior portion of the third ventricle
AVP Vasopressin
Cl Lithium clearance
CNa Sodium clearance
CCh Carbachol
CNS Central nervous system
FENa Fractional sodium excretion
FEPPNa Fractional post-proximal sodium excretion
GFR Creatinine clearance
c.c.v. Intracerebroventricular
LV Right lateral ventricle
MHS Hypertensive rats of the Milan strain
NE Norepinephrine
Pz \(\alpha_1\)-Adrenoceptor (prazosin) antagonist
SHR Spontaneously hypertensive rats
WR Wistar Kyoto rats
Yo \(\alpha_2\)-Adrenoceptor (Yohimbine) antagonist
Introduction

The involvement of the central nervous system (CNS) in the control of blood pressure and water–electrolyte homeostasis has been demonstrated in several studies [1–4]. It has long been known that there is an association between the hypothalamus and water and electrolyte excretion by the kidneys [1, 5, 6]. Cholinergic and adrenergic stimulation of the septal area, lateral hypothalamus, subfrontal organ, and the anterior region of the third ventricle (AV3V) induces dose-related natriuresis accompanied by, but to a lesser extent, kaliuresis [1, 7–12]. Studies have also shown that electrolytic lesion of the hypothalamic regions of conscious rats reduces water and salt intake, and the pressor response to angiotensinergic, cholinergic, and noradrenergic activation of the median preoptic nucleus [13], further suggesting involvement of the hypothalamus in hydroelectrolyte homeostasis and cardiovascular control. Studies of the CNS pathways involved in regulation of electrolyte and water excretion have also revealed that these stimulation and inhibitory effects are mediated by cholinergic receptors and by alpha and beta-adrenoceptors respectively, [1, 10, 14–18]. It has also been postulated that the kidneys are of crucial importance in the pathogenesis of essential hypertension, as a consequence of a primary defect in kidney function and/or renal hemodynamics that promotes retention of sodium [19–22]. Although the precise mechanism by which blood pressure increases in spontaneously hypertensive rats (SHR) also remains to be elucidated, renal control of the fluid and electrolyte balance is believed to dominate long-term control of arterial blood pressure. Sodium metabolism disturbances seem to be important in the pathogenic process in the Okamoto–Aoki strain of SHR, because chronic consumption of excess sodium increases whereas sodium restriction usually attenuates hypertension in this species [23, 24]. In addition, cross-transplantation studies indicate that a defect in renal function is important in determining arterial pressure [25, 26]. Previous balance studies [20, 27, 28] examining urinary sodium excretion throughout 3–7-week periods provided evidence of renal dysfunction in young genetically hypertensive rats of the Milan strain (MHS), SHR, and the stroke-prone sub-strain of SHR. These studies revealed that excretion of urinary salt and water was lower than for pair-fed age-matched normotensive Wistar Kyoto rats (WR). Similar results were reported by Herlitz et al. [29] for 7-week-old SHR compared with normotensive Wistar rats, although sparse data were reported for the appropriate genetic control, WR. In view of these results, we hypothesized that presumed blunting of the natriuresis response to centrally injected cholinergic and noradrenergic agonists may affect renal tubule sodium and water transport, resulting in the inability of the kidneys to handle the hydroelectrolytic balance, and consequently, causing blood pressure enhancement. To test this hypothesis, in this study we evaluated the effect of intracerebroventricular microinjection of cholinergic and noradrenergic agonists at increasing concentrations, and muscarinic cholinergic, x1, and x2-adrenoceptor antagonists on blood pressure and urinary sodium handling in SHR, and compared the results with those from age-matched normotensive WR.

Methods

Animals and surgical procedures

The general guidelines established by the Brazilian College of Animal Experimentation (COBEA) were followed throughout the investigation. The renal tests were conducted on age-matched, male offspring of sibling-mated SHR and randomly outbred WR (aged 12 weeks after weaning). Our local colonies originated from breeding stock supplied by CEMIB/Unicamp, Campinas, SP, Brazil. Male WR and SHR (180–250 g) were chronically instrumented with an right lateral ventricle (LV) guide cannula, and kept under controlled temperature (25 °C) and lighting conditions (07:00 h–19:00 h) in individual metabolic cages, with free access to tap water and standard laboratory rodent chow (Purina rat chow: Na+ content: 135 ± 3 μEq/g; K+ content: 293 ± 5 μEq/g) for seven days before the experiments. Briefly, the animals were anesthetized by intraperitoneal injection of sodium pentobarbital (50 mg kg–1 body weight) and a stainless steel cannula was stereotaxically implanted into the right LV, by use of techniques reported elsewhere and pre-established coordinates: anteroposterior +0.2 mm from bregma; lateral +1.5 mm; and vertical −4.5 mm [30, 31]. Rats were allowed one-week recovery before testing for cannula patency and position. The position of the cannula was visually confirmed by infusion of blue Evans 2 % through the i.c.v. cannula at the end of the experiment. Data from animals with incorrectly placed cannulas were excluded from statistical analysis.

Renal function test

Renal function tests were performed at 12 weeks of age on conscious, unrestrained SHR and WR. To evaluate the effect of intracerebroventricular cholinergic drug carbachol (carbamylcholine chloride) and noradrenergic (norepinephrine) drug microinjections on tubular sodium handling, the rats were randomly assigned to one of three groups (a, b, and c). Fourteen hours before the renal test,
60 µmol LiCl/100 g⁻¹ body weight was given by gavage. At 8:00 a.m., after an overnight fast with free access to water, each animal received tap water by gavage (5 % of body weight), followed by the same volume 1 h later. Immediately before experiments, the animals’ (WR and SHR) water supply was removed from the home cage. The indwelling obturator was replaced by a 30-gauge stainless steel injector at the end of PE-10 tubing connected to a 10 µl Hamilton syringe completely filled with test solution. Afterwards, 30 min after the second volume of water, the drugs carbachol (CCh, n = 12 for each dose) (group a), norepinephrine (NE, n = 12 for each dose) (group b), Sigma Chemical, or a similar volume of 0.15 M NaCl (vehicle, n = 12) (group c) was microinjected into the LV in a volume of 3 µl at different concentrations (CCh: 0.7, 1.4, 2.8 and 5.6 nmol; NE: 7.5, 15.0, 30.0 and 60.0 nmol of a different group of animals) with a 10-µl Hamilton microsyringe and urine spontaneously voided over four periods of 30 min was collected into graduated centrifuge tubes. To examine the effect of antagonist after LV administration of 2.8 nmol CCh or 30 nmol NE, rats were randomly assigned to one of four specific experimental groups and a selective cholinergic antagonist (4 nmol atropine, Atr) (group d), α1-adrenoceptor antagonist (4 nmol prazosin, Pz) (group e), α2-adrenoceptor antagonist (4 nmol Yohimbine, Yo) (group f), or vehicle (0.15 M NaCl) (group g) was LV microinjected 30-min before the agonist in a volume of 1 µl. At the end of the experiment, blood samples were drawn by cardiac puncture from anesthetized rats and urine and plasma samples were collected for analysis [17, 18, 20, 31].

Blood pressure measurement

For some of the animals in all the groups, systolic blood pressure (SBP) was measured 30 min before and after LV cholinergic (2.8 nmol CCh) and 30 nmol noradrenergic agonist and/or antagonist administration, then twice at 60-min intervals for conscious SHR and WR, by use of an indirect tail-cuff method with an electrophygmonometer combined with a pneumatic pulse transducer and/or amplifier (ITLC Life Science BpMonWin Monitor Version 1.33). This indirect approach enabled repeated measurements with close correlation (correlation coefficient = 0.975), compared with direct intra-arterial recording [4, 20, 30]. Systolic blood pressure was measured, in the morning, from 9:00 to 11:00 h. The mean of three consecutive readings was used as the blood pressure.

Data presentation and statistical analysis

All numerical results are expressed as mean ± SD for the number of experiments indicated. Plasma and urine sodium, potassium, and lithium concentrations were measured by flame photometry (Micronal B262, São Paulo, Brazil). Creatinine concentrations were determined spectrophotometrically (Instruments Laboratory, Genesys V, USA). Creatinine clearance was used to estimate glomerular filtration rate (GFR), and lithium clearance (CLi) was used to assess proximal tubule output [20, 30, 31]. Fractional sodium excretion (FENA) was calculated as CNa/Cr × 100, where CNa is sodium clearance and Cr is creatinine clearance. Fractional proximal (FEPNa) and post-proximal (FEPPNa) sodium excretion were calculated as CLi/Cr × 100 and CNa/CLi × 100, respectively. Data obtained over time were analyzed by use of repeated measures two-way ANOVA. Post hoc comparisons between selected means were performed with Bonferroni’s contrast test when initial ANOVA indicated statistical differences between experimental groups. Comparisons involving only two means within or between groups were performed by use of a Student’s t test. The level of significance was set at P ≤ 0.05.

Results

Blood pressure and renal function data (expressed as mean ± SD) for 12-week-old SHR (n = 12 in each experimental group) and WR (n = 12 in each experimental group) are summarized in Figs. 1, 2, 3, 4, and 5 and Table 1. Basal tail arterial blood pressure among 12-week-old SHR averaged 185.7 ± 9 mmHg for SHR and 126 ± 11 mmHg for WR (P ≤ 0.01). There were no significant differences between the weekly sodium consumption, serum sodium, and potassium and lithium levels (Table 1) in WR compared with the age-matched SHR group. Initial body weight was slightly, but significantly, lower among SHR. However, SHR grew less rapidly over their lifetime, and a significant difference was observed 12 weeks of life compared with the age-matched WR group. This study revealed a rapid, transient, but significant blood pressure increase after LV microinjection of 2.8 nmol CCh, action blocked by previous administration of 4 nmol atropine. Similarly, norepinephrine LV injection also enhanced, transiently, arterial blood pressure, an effect which, in turn, was attenuated by α1-adrenoceptor antagonists (4 nmol prazosin) (Fig. 1b) and was unchanged by α2-receptor antagonist (4 nmol yohimbine) (Fig. 1c).

Renal function data—dose-response curve for CCh-induced sodium excretion response

The data for renal function among 12-week-old normotensive and hypertensive (WR and SHR) groups are summarized in Figs. 1, 2, 3, 4, and 5. Urinary flow (data not included) and glomerular filtration rates, estimated by
measurement of creatinine clearance, did not differ significantly among the groups during the renal tubule sodium handling studies. Intracerebroventricular microinjections of 0.7, 1.4, 2.8, and 5.6 nmol of carbachol (CCh) in 3 μl induced a dose-dependent increase in urinary sodium, lithium, and potassium excretion by 12-week-old WR and SHR rats (Fig. 2) compared with controls (0.15 M NaCl). This increased urinary ions excretion was accompanied by predicted antidiuresis similar to that observed after CCh LV administration at the 40th minute for both groups, WR and SHR. After 60 min, i.e., 30 min after CCh microinjection, natriuresis and kaliuresis increased, reaching maximum values after 40 and 60 min. After dose–response experiments (Fig. 2), a dose of 2.8 nmol CCh was selected as optimum for the rest of the study. The effect of 2.8 nmol CCh on increasing renal fractional sodium excretion was significantly higher for WR than for SHR (P ≤ 0.001).

(Fig. 3b). This consistently increased FE_{Na} for WR was accompanied by significant enhancement of proximal (from 26.7 ± 8.6 to 77.5 ± 12.8 %, P = 0.001) and post-proximal (from 2.86 ± 0.49 to 9.36 ± 2.96 %, P = 0.001) sodium excretion and, for SHR, by a smaller but significant increase in proximal (from 29.6 ± 6.8 to 52.6 ± 8.1 %) and post-proximal (from 3.09 ± 0.37 to 6.14 ± 0.62 %) sodium excretion (P = 0.002 and P = 0.001, respectively) (Fig. 3c, d). The increase occurred in association with unchanged C_{Cr} (Fig. 3a). Likewise, the C_{Cr} and higher natriuresis and kaliuresis responses observed for WR and SHR were significant and similarly attenuated by previous LV treatment of animals with 4 nmol atropine (Figs. 2, 3).
**Dose-response curve for NE-induced sodium excretion response**

Intracerebroventricular microinjections of 7.5, 15.0, 30, and 60 nmol NE in 3 μl volume promoted dose-dependent increases in urinary sodium and potassium excretion over 120 min among 12-week-old WR; this effect was significantly attenuated in WR and SHR (Fig. 2). No changes in plasma sodium, lithium, or potassium levels were also observed in any of the experimental groups. After dose-response experiments (Fig. 2), a dose of 30 nmol NE was selected as optimum for the rest of the study. The effect of 30 nmol NE on increasing renal fractional sodium excretion was significantly higher for WR than for SHR (P ≤ 0.001) (Figs. 4b, 5b). This consistent increase of $\text{FEN}_a$ among WR was accompanied by significant enhancement of proximal (from basal 38.3 ± 9.5 to 73.3 ± 21.2 %, P = 0.001) and post-proximal (from basal 1.86 ± 0.37 to 7.13 ± 2.74 %, P = 0.001) sodium excretion; for SHR a smaller but significant increase in proximal (from 42.9 ± 8.3 to 54.7 ± 7.6 %) and post-proximal (from 2.36 ± 0.38 to 5.12 ± 0.62 %) sodium excretion was observed (P = 0.002 and P = 0.001, respectively) (Figs. 4c, d, 5c, d). The increase occurred in association with unchanged $\text{C}_{\text{CR}}$ (Figs. 4, 5a). Likewise, the $\text{C}_{\text{CR}}$, higher natriuresis, and kaliuresis responses observed for WR and SHR were significantly and similarly attenuated by previous LV treatment of the animals with 4 nmol prazosin (Figs. 2, 3, 4, and 5). The effects of blockage of LV adrenoreceptors on urinary sodium excretion was also studied for both types of rat bearing implanted cannulas. This study revealed the participation of LV $\alpha_1$ and $\alpha_2$-adrenergic receptors in regulation of renal sodium and potassium excretion. The natriuretic and kaliuretic effects of 30 nmol noradrenaline injection on LV were abolished by previous local injection of an $\alpha_1$-adrenergic antagonist (4 nmol prazosin) (P = 0.001) for both types of rat (Figs. 2, 4, and 5). These findings also support the observation that LV pre-injection of 4 nmol yohimbine, an $\alpha_2$-adrenergic antagonist, synergically potentiated the action of noradrenaline in SHR (Fig. 5). Note that prazosin (Fig. 4b) significantly inhibited fractional sodium excretion.
whereas yohimbine (Fig. 5b) enhanced fractional sodium excretion. Surprisingly, the LV yohimbine pretreatment normalized urinary sodium excretion by SHR compared with age-matched WR. ($P < 0.001$).

**Discussion**

Studies have shown that the CNS regulatory mechanisms affect the kidney, maintaining sodium homeostasis under conditions in which arterial blood pressure remains stable [1, 3, 13–19]. The importance of the renal sympathetic nerves to natriuretic control in SHR is indicated by studies showing that chronic renal denervation abolishes the reduced sodium excretion responses among these rats [19, 20, 27, 28]. Many investigators, studying mammalian species, have demonstrated that administration of cholinergic and noradrenergic agonists, and administration of antagonists, on blood pressure and urinary sodium handling, estimated on the basis of lithium clearance by adult SHR compared with appropriate age-matched WR controls. Of particular interest, confirming results from different stimulation techniques [5, 6, 14, 16], this study revealed a rapid, transient, but significant blood pressure increase after LV microinjection of CCh. The study also confirmed that i.c.v. cholinergic-induced natriuresis among WR and SHR was significantly abolished by previous LV administration of atropine. However, the natriuretic effect of i.c.v. CCh administration was significantly lower among hypertensive rats than among the normotensive strain and was associated with transient and similar antidiuresis for both WR and age-matched SHR.

Similarly, noradrenergic stimulation of LV also transiently enhances blood pressure; this effect was, in turn, attenuated by $\alpha_1$-adrenoceptor antagonist and unchanged by $\alpha_2$-receptor antagonist i.c.v. microinjections. This study confirms the participation of LV $\alpha_1$ and $\alpha_2$-adrenoceptors...
Fig. 5 Effect of lateral ventricle (LV) microinjection of 0.15 M NaCl (Control), and 30 nmol norepinephrine (NE) or 30 nmol norepinephrine + 4 nmol yohimbine on creatinine clearance (CCr, a), fractional sodium excretion (FENa, b), proximal (FEPPNa, c) and post-proximal (FEPPNa, d) fractional sodium excretion and fractional potassium excretion (FEK, e) 60-min (Post-CCh, n = 12) and 120-min (Re-Control) after LV drug administration to Wistar Kyoto rats (WR) compared with the response of spontaneously hypertensive rats (SHR). Results are reported as mean ± SD. *vs. WR Control; † vs. NE WR; ‡ vs. SHR Control; † vs. NE SHR; P ≤ 0.05 (ANOVA two-way and Bonferroni’s contrast test)

Table 1 Body weight, sodium intake, serum sodium, potassium and lithium levels for spontaneously hypertensive (SHR) compared with normotensive (WR) rats fed a standard diet

| Group      | Na⁺ (mM) | K⁺ (mM) | Li⁺ (µM) | Body weight (g) 12-week-old | Sodium intake (mmol/week/100 g b.w.) |
|------------|----------|---------|----------|-----------------------------|--------------------------------------|
| WKy (n = 12) | 138 ± 2.6 | 4.3 ± 0.6 | 85 ± 19 | 232 ± 15                    | 12.7 ± 2.3                          |
| SHR (n = 12) | 142 ± 3.1 | 4.1 ± 0.4 | 79 ± 15 | 180 ± 13*                   | 11.8 ± 1.9                          |

Results are reported as mean ± SD. *P ≤ 0.05 vs. WR (Student’s t test)

in regulation of renal sodium and potassium excretion. This conclusion is based on results showing that the natriuretic and kaliuretic effects of injection of noradrenaline into the LV are abolished by previous local injection of an α1-adrenergic antagonist (prazosin), in both groups. These findings also support the observation that LV pre-injection of yohimbine, an α2-adrenoceptor antagonist, synergically potentiated the action of noradrenaline. Note that prazosin significantly inhibited fractional sodium excretion whereas yohimbine enhanced fractional sodium excretion. Surprisingly, LV yohimbine pretreatment normalized urinary sodium excretion in SHR compared with age-matched WR. This study confirmed that CCh and NE, when centrally microinjected into conscious rats, leads to a very predictable and reproducible absolute and fractional natriuretic response accompanied by a smaller amount of kaliuresis. This response was associated with an increase in proximal and post-proximal sodium excretion without changes in glomerular filtration rate. The similar plasma lithium, sodium, and potassium levels of the experimental groups, with the absence of variation in glomerular filtration rate, indicate that the values calculated for filtered
amounts of those ions were the same after all treatments. Thus, the observed increase in renal sodium and potassium excretion is probably because of the inability of renal tubules to handle these electrolytes, with disruption of glomerulotubular balance.

Despite repeated demonstration of the natriuretic effect of central CCh and NE administration to a variety of species, to the best of our knowledge there has been no previous description of these effects among SHR and the precise mechanism of this phenomenon remains unknown. Our results suggest that the effect of LV cholinergic and noradrenergic homeostatic on hydroelectrolytic balance and blood pressure control is impaired in SHR. This mechanism be important in the development and maintenance of hypertension in SHR. Several possibilities should be considered. First, the central nervous system may directly affect renal sodium excretion via neural routes. Second, hemodynamic factors may be responsible for alteration of electrolyte excretion. Third, the natriuresis may result from fluctuations in the level of neural-borne factors which may affect sodium and/or water transporters in renal tubules and, consequently, sodium handling. Fourth, the SHR findings suggest the definite lack of a relationship between the activity of LV neurotransmitters and/or expression of receptors and peripheral renal response in that strain.

The time course, magnitude, and specificity of the natriuretic response to central microinjection of carbachol into rats have been well characterized [5, 6, 10, 11, 17, 18]. Mechanisms usually proposed to explain the cause or mediation of natriuresis include inhibition of renal nerve activity [14–16]; increases in renal perfusion pressure, glomerular filtration rate, or renal plasma flow [33, 35]; and release of vasopressin or other hormones that inhibit tubule absorption of sodium [5, 36]. However, previous studies suggest that the natriuresis seen after central cholinergic stimulation in conscious rats is not mediated by inhibition of renal nerve activity or by changes in plasma concentrations of renin and aldosterone [7–14, 33], and is not associated with significant alterations in glomerular filtration rate [16–18].

It is, however, known that central administration of vasopressin (AVP) causes significant natriuresis [37–39]. In addition, acetylcholine stimulates concentration-dependent release of AVP from the hypothalamic nucleus. It also increases AVP release in vivo when administered by way of the carotid artery or into the cerebral ventricles [40–42] and it increases the electrical activity of supraoptic neurons when iontophoresed on to them in vivo [40, 43] or when added to the superfusion medium in vitro [44]. Thus, in this study, the natriuretic effect induced by CCh after LV administration may be caused, at least in part, by enhanced secretion of AVP from the posterior pituitary. Studies showing elevation of the AVP content of the posterior pituitary and reduced hypothalamic AVP content [45, 46] in adult SHR compared with WR suggest abnormalities in the synthesis and/or release of AVP by SHR. In our study, the attenuation of cholinergic responsiveness among 16-week-old SHR compared with age-matched WR suggests that either that the system is inhibited by the higher blood pressure present at this age or the chronic exposure to this high blood pressure has permanently altered the responsiveness of the hypothalamus–pituitary system to signals controlling AVP release. Thus, over responsiveness might result in significantly greater circulating AVP concentrations, which could potentially contribute to the development of hypertension. Conversely, for adult SHR reduced hypothalamic contents of AVP may explain the attenuated response to LV administration of CCh to these rats.

When central noradrenergic neurons in both SHR and WR were destroyed by intracerebroventricular injection of 6-hydroxydopamine, carbachol-induced vasopressor responses were markedly augmented, and resulted in responses similar to those of SHR. These findings indicate that central noradrenergic vasodepressive neurons are deficient and that the augmented vasopressor responses to carbachol resulted from deranged central noradrenergic mechanisms in SHR. A study by Yamada et al. [47] also revealed a specific increase in muscarinic receptors and a decrease in cholinergic activity in the hypothalamus of SHR [47]. Oprail et al. [48] have demonstrated that increased blood pressure in SHR occurs, at least in part, as a result of reduced norepinephrine release or receptors in nerve ends in the anterior hypothalamic area (AHA), thus reducing activation of sympatoinnhibitory neurons. Two mechanisms have been shown to contribute to this effect:

1. Reduced noradrenergic input into the AHA via baroreflex pathways; and
2. Local inhibition of NE release in the AHA by the inhibitory neuromodulator atrial natriuretic peptide (ANP) [48, 49].

A previous study has revealed that plasma irANP and irBNP were higher in adult SHR than in control WR, whereas ANP and BNP values of young SHR did not differ from those of control WR [49]. In the WR, excitation of NTS neurons by baroreflex afferents leads to activation of sympatoinnhibitory neurons in the NTS and AHA, strong inhibition of sympathetic nervous system outflow, and a decrease in arterial pressure. However, in the SHR brain ANP acts at the levels of the NTS and AHA to perturb this baroreflex regulatory pathway. Thus, we may suppose that ANP acts at several sites in brain to facilitate the development and maintenance of sympathetically mediated hypertension in the SHR model by reducing the number or activation of central sympatoinnhibitory neurons.
The novel findings of this work show that the reduced natriuretic effect of central NE stimuli in SHR was associated with unchanged creatinine clearance and reduced ion delivery from the proximal tubule incompletely compensated by more distal nephron segments. This effect demonstrates diminished NE graded-fashion responses with a rightward shift of the dose–response curve, providing evidence of down-regulation of target organ responsiveness to SHR LV stimuli. The mechanisms underlying this phenomenon are still not well understood but may be related to renal sodium handling. We have previously demonstrated that the urinary sodium excretion response to central insulin, angiotensin II, and hypertonic saline was strikingly and similarly attenuated in adult SHR compared with age-matched WR controls [30, 31, 50]. Because hemodynamic and natriuretic responses seem to depend on the magnitude of increased blood pressure, the inability of hypertensive kidneys to achieve effective natriuresis after centrally administered NE may reflect the ineffectiveness of inhibiting sympathetic activity responses and/or modifying the higher basal arterial pressor levels in SHR. There is evidence of the importance of renal sympathetic nerve activity in the pathogenesis of experimental models of hypertension [3, 19, 20]. In this case, the significant reduced natriuretic response among young SHR compared with WR may reflect differences in efferent renal nerve activity, which is reported to be higher for SHR as young as 5 weeks [20, 27, 28].

It is well known that stimulation of α2-adrenoceptors in the brainstem, a cardiovascular region, induces a reduction in blood pressure. Carrettiero et al. [49] reported fewer α2-adrenoceptors in SHR than in WR in all NTS subnuclei and for different ages. This reveals the importance of α2-receptor distribution within the NTS with regard to neural control of blood pressure and the development of hypertension. Other studies have also revealed that after central α2-adrenoreceptor stimulation in conscious rats, urinary sodium excretion is selectively mediated by downstream Gz12, but not Gz11, Gz13, Gz6, or Gz5, subunit GTP-binding regulatory protein signal transduction pathways [51–53]. These authors revealed, in particular, that the brain Gz12-protein-mediated sympathoinhibitory renal nerve-dependent pathway and is of critical importance in the central neural mechanisms activated to maintain fluid and electrolyte homeostasis. The underlying mechanisms by which brain Gz12-subunit protein-gated pathways induce α2-adrenoreceptor-evoked sodium control in vivo are unknown. In this study, given the intimate association between fluid and electrolyte homeostasis and the long-term control of arterial pressure, we may speculate that downregulation of brain Gz12 protein expression in SHR may lead to elevated sympathetic drive, renal sodium retention, and the development of renal nerve-dependent hypertension.

Our experiments furnished good evidence of the existence of a central adrenergic mechanism consisting of α1 and α2 receptors which work antagonistically on regulation of renal sodium excretion. We may suppose that stimulation of central nervous system α2-adrenergic receptors prevents basal increased renal sympathetic overexcitability in conscious SHR. This conclusion is based on two main findings. First, the effect of LV administration of norepinephrine on natriuresis is significantly attenuated in SHR. Second, pretreatment with α2-adrenergic receptor antagonists reversed the effects of the LV NE injection, which demonstrates that central α2-adrenergic receptors are involved in the reduced natriuresis observed for the hypertensive strain [54–56]. Because LV administration of yohimbine alone increases the natriuretic response in SHR but not in WR, we may hypothesize that the basal activity of these central α2-adrenergic receptors may be very high. However, we may not discount the possibility that SHR neural synapses have more α2-adrenergic receptors than those of WR. In fact, the natriuresis resulting from injection of norepinephrine into the LV of SHR was potentiated by yohimbine and blocked by prazosin. Because adrenergic agonist or antagonists did not alter glomerular filtration rate, changes in renal hemodynamics do not explain the natriuresis. The natriuresis resulting from yohimbine could also be because of:

1. inhibition of renal sympathetic nerve activity by a central α2-adrenoceptor mechanism; and/or
2. α2-adrenergic receptor-induced inhibition of vasopressin release from the central nervous system [17, 18, 28, 49].

It is more likely that natriuresis is a result of reduced renal sympathetic nerve activity and a consequent decrease in renal tubular reabsorption of sodium. Norepinephrine administration into the ventromedial hypothalamus, lateral hypothalamus, septal area, and third ventricle of conscious rats increases urinary sodium excretion; the natriuresis is prevented by central α-adrenergic receptor blockade and potentiated by α2-adrenergic receptor blockade [17, 18, 54–56]. These studies, with our results, suggest an inhibitory effect of central α2-adrenergic receptors on urinary sodium excretion and an excitatory effect of central α1-adrenoceptors. In conclusion, our results suggest striking participation of central cholinergic and/or adrenergic receptors in the renal pathogenesis of genetic hypertension in SHR. Although the precise mechanism of the different natriuretic response of WR and SHR is still uncertain, these results led us to speculate that inappropriate neural cholinergic and noradrenergic pathways may have crucial effects on renal tubule sodium and water transport, resulting in the inability of kidneys to control hydrolelectrolytic balance, and, consequently, an increase in blood pressure.
Acknowledgments  This research was supported by CNPq (no. 500868/91-3), CAPES and FAPESP (10/52696-0).

Conflict of interest  We affirm there is no conflict of interest.

References

1. Gontijo JR, Kopp UC (1994) Renal sensory receptor activation by calcitonin gene-related peptide. Hypertension 23:1063–1067
2. Gontijo JA, Garcia WE, Figueiredo JF, Silva-Netto CR, Furtado MR (1992) Renal sodium handling after noradrenergic stimulation of the lateral hypothalamic area in rats. Braz J Med Biol Res 25:937–942
3. DiBona GF (2000) Neural control of the kidney: functionally specific renal sympathetic nerve fibers. Am J Physiol Regul Integr Comp Physiol 279:R1517–R1524
4. Scabara JE, de Lima MC, Lopes A, de Lima IP, Mesquita FF, Bráz Torres D, Boer PA, Gontijo JA (2013) Impact of taurine supplementation on blood pressure in gestational protein-restricted offspring: Effect on the medial solitary tract nucleus cell numbers, angiotensin receptors, and renal sodium handling. J Renin Angiotensin Aldosterone Syst
5. Silva-Netto CR, Jackson RH, Colindres RE (1985) Study of sodium and potassium excretion after renal denervation and cholinergic stimulation of the lateral hypothalamic area of the rat. Braz J Med Biol Res 18:29–36
6. Silva-Netto CR, Jackson RH, Colindres RE (1986) Cholinergic stimulation of the hypothalamus and natriuresis in rats: role of the renal nerves. Am J Physiol 250:F322–F328
7. Dorn J, Antunes-Rodrigues J, McCann SM (1970) Natriuresis in the rat following intraventricular carbachol. Am J Physiol 219:1292–1298
8. Pillar AX, Silva-Netto CR, Camargo LA, Saad WA, Antunes-Rodrigues J, Covian MR (1977) Adrenergic stimulation of the lateral hypothalamic area on sodium and potassium excretion. Pharmacol Biochem Behav 6:145–149
9. Camargo LA, Saad WA, Netto CR, Gentil CG, Antunes-Rodrigues J, Covian MR (1976) Effects of catecholamines injected into the septal area of the rat brain on natriuresis, kaliuresis and diuresis, Can J Physiol Pharmacol 54:219–228
10. Saad WA, Camargo LA, Graeff FG, Silva-Netto CR, Antunes-Rodrigues J, Covian MR (1976) The role of central muscarinic and nicotinic receptors in the regulation of sodium and potassium renal excretion. Gen Pharmacol 7:145–148
11. Brody MJ, Haywood JR, Touw KB (1980) Neural mechanisms in hypertension. Annu Rev Physiol 42:441–453
12. Bealer SL (1983) Hemodynamic mechanisms in CNS-induced natriuresis in the conscious rat. Am J Physiol 244:F376–F382
13. Covian MR, Antunes-Rodrigues J, Gentil CG, Saad WA, Camargo LA, Silva Neto CR (1975) Central control of salt balance. In: Morgenson GJ, Calaresu FR (eds) Neural integration of physiological mechanisms and behavior (JAF Stevenson Memorial Volume). University of Toronto Press, Toronto, pp 267–285
14. Silva-Netto CR, Jackson RH, Colindres RE (1983) Factors causing natriuresis after hypothalamic injection of a cholinergic drug in rats. Am J Physiol 244:F64–F69
15. Franci CR, Silva-Netto CR, Saad WA, Camargo LA, Antunes-Rodrigues J (1980) Interaction between the lateral hypothalamic area (LHA) and the medial septal area (MSA) in the control of sodium and potassium excretion in rats. Physiol Behav 25:801–806
16. Silva-Netto CR, de Aires MM, Malnic G (1980) Hypothalamic stimulation and electrolyte excretion: a micropuncture study. Am J Physiol 239:F206–F214
17. Gontijo JA, Garcia WE, Figueiredo JF, Silva-Netto CR, Furtado MR (1991) Renal water handling evaluated by lithium clearance following adrenergic and cholinergic stimulation of the lateral hypothalamic area. Braz J Med Biol Res 24:837–842
18. Gontijo JA, Silva-Netto CR, Furtado MR (1990) Effects of injection of selective adrenergic receptor antagonists into the lateral hypothalamic area on renal function. Braz J Med Biol Res 23:1205–1208
19. Johns EJ, Kopp UC, DiBona GF (2011) Neural control of renal function. Comp Physiol 1:731–767
20. Boer PA, Morelli JM, Figueiredo JF, Gontijo JA (2005) Early altered renal sodium handling determined by lithium clearance in spontaneously hypertensive rats (SHR): role of renal nerves. Life Sci 76:1805–1815
21. Xu J, Hering D, Sata Y, Walton A, Krum H, Esler MD, Schlaich MP (2014) Renal denervation: current implications and future perspectives. Clin Sci Lond 126:41–53
22. Hall JE, Granger JP, Do Carmo JM, da Silva AA, Dubinjon J, Hamza S, Speed J, Hall ME (2012) Hypertension: physiology and pathophysiology. Comp Physiol 2:2393–2442
23. Aoki K, Yamori Y, Ooshima A, Okamoto K (1972) Effects of high or low sodium intake in spontaneously hypertensive rats. Jap Circ J 36:539–545
24. Louis WJ, Tabei R, Spector S (1971) Effects of sodium intake on inherited hypertension in the rat. Lancet 2:1283–1286
25. Bianchi G, Fox U, Imbasciati E (1974) The development of a new strain of spontaneously hypertensive rats. Life Sci 14:339–347
26. Bianchi G, Baer FG, Fox U, Duzzi L, Pagetti D, Giovannetti AM (1975) Changes in renin, water balance, and sodium balance during development of high blood pressure in genetically hypertensive rats. Circ Res 36(37):153–161
27. Opali S, Sripairojthikoon W, Wyss JM (1987) The renal afferent nerves in the pathogenesis of hypertension. Can J Physiol Pharmacol 65:1548–1558
28. Beierwaltes WH, Arendshorst WJ, Klemmer PJ (1982) Electrolyte and water balance in young spontaneously hypertensive rats. Hypertension 4:908–915
29. Herlitz H, Lundin S, Ricksten SE, Gothberg G, Aurell M, Hallbiick M, Berglund G (1979) Sodium balance and structural vascular changes in the kidney during development of hypertension in spontaneously hypertensive rats. Acta Med Scand 206(suppl 625):111
30. Guadagnini D, Gontijo JA (2006) Altered renal sodium handling in spontaneously hypertensive rats (SHR) after hypertonic saline intracerebroventricular injection: role of renal nerves. Life Sci 20(79):1666–1673
31. Menegon LF, Zapolari A, Boer PA, de Almeida AR, Gontijo JA (2008) Long-term effects of intracerebroventricular insulin microinjection on renal sodium handling and arterial blood pressure in rats. Brain Res Bull 76:344–348
32. Andersson B, Daume MF, Olsson K (1969) Evidence for a hypothalamic control of renal sodium excretion. Acta Physiol Scand 75:496–510
33. Chiu PJS, Sawyer WH (1974) Third ventricular injection of hypertonic sodium chloride and natriuresis in cats. Am J Physiol 226:463–469
34. Rohmieux P, Beyer C, Nagy E, Tschope C, Hohle S, Strauch M, Unger T (1995) NaCl injections in brain induce natriuresis and blood pressure responses sensitive to ANG II AT1 receptor. Am J Physiol 1995(269):F282–F288
35. Beeler SL (1983) Renal sodium and potassium excretion in rats. Brain Res Bull 25:937–942
36. Pierce ET, Grekin RJ, Mouw DR (1984) Efferent role of ADH in CNS-induced natriuresis. Am J Physiol 246:F32–F38
37. Blanch GT, Freiria-Oliveira AH, Murphy D, Paulin RF, Antunes-Rodrigues J, Colombari E, Menani JV, Colombari DS (2013) Inhibitory mechanism of the nucleus of the solitary tract involved in the control of cardiovascular, dipsogenic, hormonal, and renal responses to hyperosmolality. Am J Physiol Regul Integr Comp Physiol 304:R531–R542

38. Ishikawa S, Fujita N, Fujisawa G, Tsuboi Y, Sakuma N, Okada K, Saito T (1996) Involvement of arginine vasopressin and renal sodium handling in pathogenesis of hyponatremia in elderly patients. Endocr J 43:101–108

39. Nishida Y, Hosomi H, Bishop VS (1997) Long-term effects of AVP-induced neurohumoral interaction via area postrema on body fluid and blood pressure. Am J Physiol 273:R1696–R1703

40. Shi L, Mao C, Zeng F, Zhang Y, Xu Z (2008) Central cholinergic signal-mediated neuroendocrine regulation of vasopressin and oxytocin in ovine fetuses. BMC Dev Biol 8:95

41. Lauand F, Ruginsk SG, Rodrigues HL, Reis WL, de Castro M, Elias LL, Antunes-Rodrigues J (2007) Glucocorticoid modulation of atrial natriuretic peptide, oxytocin, vasopressin and Fos expression in response to osmotic, angiotensinergic and cholinergic stimulation. Neuroscience 147:247–257

42. Xu Z, Pekarek E, Ge J, Yao J (2001) Functional relationship between subfornical organ cholinergic stimulation and cellular activation in the hypothalamus and AV3V region. Brain Res 922:191–200

43. Wolfe SA Jr, Gainer H (1986) Effects of calcium on frequency-modulated secretion of vasopressin from isolated murine neural lobes. Brain Res 399:190–193

44. Nakatsu K, Ohgo S, Oki Y, Matsukura S (1991) Interleukin-1 (IL-1) stimulates arginine vasopressin (AVP) release from superfused rat hypothalamo-neurohypophyseal complexes independently of cholinergic mechanism. Brain Res 554:38–45

45. Stepniakowski K, Budzikowski A, Lon S, Szczechanska-Sadowska E (1991) Central ANP attenuates pressor responses to central AVP in WKY and SHR. Brain Res Bull 27:247–249

46. Magnusson K, Meyerson BJ (1996) Strain, age and sex differences in the release of vasopressin from the pituitary: a study in the spontaneously hypertensive (SHR) and Wistar-Kyoto (WKY) rat. Neuropeptides 30:465–470

47. Yamada S, Ishima T, Hayashi M, Tomita T, Hayashi E (1984) Muscarinic cholinoceptors and choline acetyltransferase activity in the hypothalamus of spontaneously hypertensive rats. Life Sci 34:2151–2158

48. Oparil S, Chen YF, Peng N, Wyss JM (1996) Anterior hypothalamic norepinephrine, atrial natriuretic peptide, and hypertension. Front Neuroendocrinol 17:212–246

49. Carreccio DC, Ferrari MF, Fior-Chadi DR (2012) α2-Adrenergic receptor distribution and density within the nucleus tractus solitarii of normotensive and hypertensive rats during development. Auton Neurosci 166:39–46

50. Zapparoli A, Calegari V, Velloso LA, Guadagnini D, Boer PA, Gontijo IA (2010) Hypothalamic SOCS-3 expression and the effect of intracerebroventricular angiotensin II injection on water intake and renal sodium handling in SHR. J Physiol Sci 60:425–433

51. Wainford RD, Kapusta DR (2012) Functional selectivity of central Gαi-subunit proteins in mediating the cardiovascular and renal excretory responses evoked by central α2-adrenoceptor activation in vivo. Br J Pharmacol 166:210–220

52. Kapusta DR, Pascale CL, Wainford RD (2012) Heterotrimeric Gai2-subunit protein-gated pathways mediate central sympathoinhibition to maintain fluid and electrolyte homeostasis during stress. FASEB J 26:2776–2787

53. Wainford RD, Kapusta DR (2012) Hypothalamic paraventricular nucleus Gαq subunit protein pathways mediate vasopressin dysregulation and fluid retention in salt-sensitive rats. Endocrinology 151:5403–5414

54. Kapusta DR, Knardahl S, Koepke JP, Johnson AK, DiBona GF (1989) Selective central α2-adrenoceptor control of regional haemodynamic responses to air jet stress in conscious spontaneously hypertensive rats. J Hypertens 7:189–194

55. Koepke JP, Jones S, DiBona GF (1988) Sodium responsiveness of central alpha 2-adrenergic receptors in spontaneously hypertensive rats. Hypertension 11:326–333

56. Koepke JP, Jones S, DiBona GF (1987) Alpha 2-adrenoceptors in amygdala control renal sympathetic nerve activity and renal function in conscious spontaneously hypertensive rats. Brain Res 404:80–88